Given the tumor heterogeneity and diverse clinical manifestations observed in NF1, adopting similar multi-omics approaches could greatly enhance patient stratification, facilitate the discovery of prognostic biomarkers, and improve our understanding of immune evasion mechanisms in NF1-associated tumors. The gene discussed is NF1; the disease is neoplasm.